Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Delivers No Evidence FDA Knew Of "Phantom" Recall - Congressional Staff

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson failed to provide proof that FDA acknowledged the firm's plan for a "phantom" recall of a Motrin product, according to Capitol Hill staff

You may also be interested in...



J&J Settlement With States Not Likely To Be Precedent In OTC Space

J&J's agreement with 42 states and Washington, D.C. is its latest cost from widespread GMP problems that prompted recalls and led to a 2011 FDA consent decree. But the unusual combination of factors suggest more such state actions are unlikely to follow.

J&J Settlement With States Not Likely To Be Precedent In OTC Space

J&J's agreement with 42 states and Washington, D.C. is its latest cost from widespread GMP problems that prompted recalls and led to a 2011 FDA consent decree. But the unusual combination of factors suggest more such state actions are unlikely to follow.

J&J Hears Consent Decree Echoes In Litigation From ‘Silent’ Motrin Recall

J&J intends to appeal to Oregon’s Supreme Court the state appellate court’s decision that the absence of proof of harm to consumers from sales of Motrin 200mg that failed to meet dissolution standards does not preclude unfair trade litigation filed by the state attorney general.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel